Study shows that the SARS-CoV-2 envelope protein potently restricts HIV-1 infection

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that envelope (E) proteins of β-coronaviruses (CoVs) could restrict human immunodeficiency virus type 1 (HIV-1) infection.

Study: The Envelope Protein of SARS-CoV-2 Inhibits Viral Protein Synthesis and Infectivity of Human Immunodeficiency Virus type 1 (HIV-1). Image Credit: NEW-LIGHT-VISUALS/Shutterstock
Study: The Envelope Protein of SARS-CoV-2 Inhibits Viral Protein Synthesis and Infectivity of Human Immunodeficiency Virus type 1 (HIV-1). Image Credit: NEW-LIGHT-VISUALS/Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a highly transmissible human CoV (HCoV), emerged in late 2019 and caused the ongoing coronavirus disease 2019 (COVID-19) pandemic. The unprecedented morbidity and mortality caused by COVID-19 have underlined the critical need to learn more about the role of viral proteins in virus pathogenesis and replication.

The E protein is a small 75 amino acid transmembrane protein encoded by the human CoVs, including SARS-CoV-2. The CoVs E protein, similar to the viroporins from the influenza A virus, i.e., matrix protein 2 (M2), and HIV-1, i.e., viral protein U (Vpu), creates an ion channel. The CoVs E protein is essential for viral pathogenicity and the successful release of infectious viruses into the host.

About the study

In the current work, the researchers evaluated the infectivity of the HIV-1 virus in the vicinity of four distinct β-CoV E proteins. The scientists analyzed the biological characteristics of four β-CoVs (SARS-CoV-2, SARS-CoV, Middle East respiratory CoV (MERS-CoV), and HCoV-OC43) E proteins in the presence of HIV-1.

Vectors encoding the HIV-1 genome and CoVs proteins were transfected into human embryonic kidney 293 (HEK293) cells. HIV-1 infectivity was quantified using the TZM-bl cell line (derived from Henrietta Lacks cell clone). The National Institutes of Health (NIH) HIV Reagent Branch of America provided plasmids encompassing the complete HIV-1 NL4-3 genome, i.e., pNL4-3 and pNL4-3ΔVpu. Immunofluorescence investigations of COS-7 cell (African green monkey kidney fibroblast-like cell line) transfections were used to determine SARS-COV-2 E protein intracellular localization. 

Results and discussions

The results showed that co-transfection of HEK293 cells with vectors encoding the SARS-CoV-2 E protein and plasmids containing either the HIV-1ΔVpu or HIV-1 (strain NL4-3) genomes significantly limited the infectious HIV-1 release; similar to the herpes simplex virus 1 (HSV-1) glycoprotein D (gD) protein. Immunoprecipitation of SARS-CoV2 E proteins and gD from cell lysates demonstrated that these proteins were expressed efficiently during co-transfections. Notably, SARS-CoV-2 E protein did not affect the synthesis of infectious HSV-1 progeny virus 24 and 48 hours following the infection.

Similar to the SARS-CoV-2 E protein, the MERS-CoV, SARS-CoV, and HCoV-OC43 E proteins were largely localized in the Golgi apparatus and endoplasmic reticulum (ER) cell regions, with no expression at the cell surface. SARS-CoV and SARS-CoV-2 E proteins lowered HIV-1 production by nearly 100-fold. Yet, HCoV-OC43 or MERS-CoV E proteins inhibited HIV-1 infectivity to a limited extent. However, replacing the significantly conserved proline within the SARS-CoV-2 E's cytoplasmic domain abolished the limitation on HIV-1 infection.

The presence of SARS-CoV and SARS-CoV-2 E proteins lowered the levels of HIV-1 proteins. By contrast, the HCoV-OC43 and MERS-CoV E proteins only reduced the HIV-1 protein synthesis moderately. The CoVs E proteins did not affect genome integration or reverse transcription of the HIV-1 virus. Nonetheless, via phosphorylating eukaryotic initiation factor 2α (eIF-2α), the SARS-CoV and SARS-CoV-2 E proteins stimulated the ER-stress pathway, which reduces protein production in cells. These observations illustrated that the SARS-CoV-2-induced restriction of HIV-1 infection was due to its E protein's capacity to stimulate eIF-2α phosphorylation.

The four CoVs E protein or SARS-CoV-2 nucleocapsid (N) proteins did not down-modulate the cell surface expression of bone marrow stromal cell antigen 2 (BST-2). Nevertheless, the HIV-1 Vpu protein and SARS-CoV-2 and SARS-CoV spike (S) proteins drastically down-regulated the BST-2 cell surface expression. Additionally, companion studies indicated that the CoVs E proteins triggered autophagy in HIV-1.

Conclusions

According to the authors, this was the first study revealing that viroporins from a heterologous virus, i.e., CoVs E proteins, could reduce HIV-1 infection.  

The study findings demonstrated that CoVs such as SARS-CoV-2 and SARS-CoV significantly limited HIV-1 infection, whereas HCoV-OC43 and MERS-CoV were less restrictive. Similar observations were seen in the amounts of HIV-1 protein production in cells. The SARS-CoV-2 E protein, instead of interfering with RNA synthesis or viral integration, lowered viral protein production. The CoVs E protein-induced ER stress leads to phosphorylation of eIF-2, which inhibits protein synthesis of HIV-1.

Lastly, the study depicted that E proteins of four CoVs and the SARS-CoV-2 N protein did not substantially lower BST-2 expression. On the contrary, the HIV-1 Vpu, SARS-CoV-2, and SARS-CoV S proteins decreased BST-2 cell surface expression. Additional investigations are required to understand the CoVs S protein domains relevant for their interactions with BST-1. 

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 12 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Shanet Susan Alex

Written by

Shanet Susan Alex

Shanet Susan Alex, a medical writer, based in Kerala, India, is a Doctor of Pharmacy graduate from Kerala University of Health Sciences. Her academic background is in clinical pharmacy and research, and she is passionate about medical writing. Shanet has published papers in the International Journal of Medical Science and Current Research (IJMSCR), the International Journal of Pharmacy (IJP), and the International Journal of Medical Science and Applied Research (IJMSAR). Apart from work, she enjoys listening to music and watching movies.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Susan Alex, Shanet. (2023, May 12). Study shows that the SARS-CoV-2 envelope protein potently restricts HIV-1 infection. News-Medical. Retrieved on December 28, 2024 from https://www.news-medical.net/news/20220330/Study-shows-that-the-SARS-CoV-2-envelope-protein-potently-restricts-HIV-1-infection.aspx.

  • MLA

    Susan Alex, Shanet. "Study shows that the SARS-CoV-2 envelope protein potently restricts HIV-1 infection". News-Medical. 28 December 2024. <https://www.news-medical.net/news/20220330/Study-shows-that-the-SARS-CoV-2-envelope-protein-potently-restricts-HIV-1-infection.aspx>.

  • Chicago

    Susan Alex, Shanet. "Study shows that the SARS-CoV-2 envelope protein potently restricts HIV-1 infection". News-Medical. https://www.news-medical.net/news/20220330/Study-shows-that-the-SARS-CoV-2-envelope-protein-potently-restricts-HIV-1-infection.aspx. (accessed December 28, 2024).

  • Harvard

    Susan Alex, Shanet. 2023. Study shows that the SARS-CoV-2 envelope protein potently restricts HIV-1 infection. News-Medical, viewed 28 December 2024, https://www.news-medical.net/news/20220330/Study-shows-that-the-SARS-CoV-2-envelope-protein-potently-restricts-HIV-1-infection.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
SARS-CoV-2 spike protein found lingering in brain regions